$JNJ The Safest Stock on the Planet. Pulling Back. Monthly BUY!Johnson & JohnsonBATS:JNJConnectmyCurrencyIf you had to pick one stock to buy and forget for a decade, most serious investors would at least consider Johnson and Johnson. 🧠 64 consecutive years of dividend increases. AAA credit rating. Two of the strongest franchises in global healthcare. A pipeline stuffed with blockbuster drugs. 💊 The stock has pulled back hard from the 52 week high and the monthly chart has printed a clean demand zone. Price has not yet reached it. That is the setup. ⏳ Q1 2026 results were strong across the board. 🏆 Revenue hit $24.1 billion, up 9.9% year over year, beating the $23.6 billion consensus by $500 million. 💰 Adjusted EPS came in at $2.70, beating expectations of $2.68. 🎯 Innovative Medicine sales hit $15.4 billion, up 11.2%, powered by Darzalex up 22.5% operationally and Tremfya up 68.3% operationally. 🚀 MedTech sales hit $8.6 billion, up 7.7%, led by strength in electrophysiology, cardiovascular and orthopaedics. 💪 The company now has 28 platforms or products generating at least $1 billion in annual revenue. That is not a pipeline. That is a machine. ⚡ Management raised guidance across every metric. 📈 Full year 2026 reported sales guidance was lifted to a midpoint of $100.8 billion, implying 7% growth. 💵 Adjusted EPS guidance was raised to a midpoint of $11.55, also implying 7.1% growth. Pre-tax operating margin is expected to improve by at least 50 basis points in 2026. 🎯 The board raised the quarterly dividend 3.1% from $1.30 to $1.34 per share, lifting the annual rate to $5.36 and extending one of the most remarkable dividend streaks in market history to 64 consecutive years. 🏅 The pipeline is equally compelling. 🔬 ICOTYDE was approved as the first and only targeted oral peptide for plaque psoriasis. TECVAYLI plus Darzalex Faspro was approved for relapsed or refractory multiple myeloma. VARIPULSE Pro received European approval with a new pulse sequence that is five times faster. 🤯 JNJ presented multiple milestone clinical trial readouts at ASCO 2026 across autoimmunity, oncology and myeloma. Management has guided towards double digit EPS growth by the end of the decade. 📅 The 52 week range sits between $149.04 and $251.71. 📊 17 analysts cover the stock with 12 Buy ratings and zero Sell ratings. Average analyst price target is $266.40 with a high target of $285.00. Dividend yield sits at 2.30%. Next earnings are due 15 July 2026. 🐂 Now the key point. ⚠️ Price has NOT yet reached the entry zone. ⏳ The monthly demand zone sits at $185.55, well below where price is currently trading at $232. This is a trade that requires patience. Set the alert. Wait for price to come to the level. Do not chase it. 🧘 🟢 Buy Zone ~ $185.55 area (0.382 Fibonacci Monthly) ⚠️ Price has not yet reached this zone. Wait for price to pull back to the level before entering. 💰 Entry: $185.55 🛑 Stop: $174.99 (5.691% below entry) 🎯 Target: $280.97 (51.4% upside from entry) 📈 Risk/Reward Ratio: 9.04 💵 Annual Dividend: $5.36 per share (2.30% yield) 🏅 Consecutive Dividend Increases: 64 years 🌍 52 Week Range: $149.04 to $251.71 📅 Next Earnings: 15 July 2026 64 years of dividend raises. 🏅 $100 billion revenue year. 💊 12 analysts say Buy. 🐂 Set the alert at $185.55 and let price come to you. 🚀 ⚠️ Not financial advice. Manage your risk.